GLOBUS MEDICAL INC
For the period ended Dec 31, 2024. Filed Feb 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 20, 2025
GMED$76.37+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Equity
| Class ACommon Stock · Class BCommon Stock · Additional paid-in · Accumulated other comprehensive · Retained | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | Shares | $ | Shares | $ | capital | income/(loss) | earnings | Total |
| Balance at December 31, 2023 | 113,906 | $114 | 22,430 | $22 | $2,870,749 | $(10,192) | $1,137,266 | $3,997,959 |
| Stock-based compensation | — | — | — | — | 54,287 | — | — | 54,287 |
| Grant of contingent restricted stock units | — | — | — | — | 2,500 | — | — | 2,500 |
| Exercise of stock options | 2,450 | 3 | — | — | 110,437 | — | — | 110,440 |
| Issuance of Class A common stock under employee and director equity option plans, net | 261 | — | — | — | (6,729) | — | — | (6,729) |
| Comprehensive income/(loss) | — | — | — | — | — | 3,331 | 102,984 | 106,315 |
| Repurchase and retirement of common stock | (1,627) | (2) | — | — | — | — | (87,437) | (87,439) |
| Balance at December 31, 2024 | 114,990 | $115 | 22,430 | $22 | $3,031,244 | $(6,861) | $1,152,813 | $4,177,333 |
| Class ACommon Stock · Class BCommon Stock · Additional paid-in · Accumulated other comprehensive · Retained | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | Shares | $ | Shares | $ | capital | income/(loss) | earnings | Total |
| Balance at December 31, 2022 | 77,762 | $78 | 22,430 | $22 | $630,952 | $(24,630) | $1,239,951 | $1,846,373 |
| Stock-based compensation | — | — | — | — | 52,773 | — | — | 52,773 |
| Grant of contingent restricted stock units | — | — | — | — | 1,925 | — | — | 1,925 |
| Exercise of stock options | 387 | — | — | — | 12,396 | — | — | 12,396 |
| Issuance of Class A common stock under employee and director equity option plans, net | 273 | — | — | — | (11,409) | — | — | (11,409) |
| Issuance of equity for NuVasive Merger | 39,813 | 40 | — | — | 2,184,112 | — | — | 2,184,152 |
| Comprehensive income/(loss) | — | — | — | — | — | 14,438 | 122,873 | 137,311 |
| Repurchase and retirement of common stock | (4,329) | (4) | — | — | — | — | (225,558) | (225,562) |
| Balance at December 31, 2023 | 113,906 | $114 | 22,430 | $22 | $2,870,749 | $(10,192) | $1,137,266 | $3,997,959 |
See accompanying notes to consolidated financial statements
| Class ACommon Stock · Class BCommon Stock · Additional paid-in · Accumulated other comprehensive · Retained | ||||||||
|---|---|---|---|---|---|---|---|---|
| (In thousands) | Shares | $ | Shares | $ | capital | income/(loss) | earnings | Total |
| Balance at December 31, 2021 | 79,114 | $79 | 22,430 | $22 | $553,787 | $(6,772) | $1,194,272 | $1,741,388 |
| Stock-based compensation | — | — | — | — | 33,466 | — | — | 33,466 |
| Grant of contingent restricted stock units | — | — | — | — | 1,985 | — | — | 1,985 |
| Exercise of stock options | 999 | 1 | — | — | 41,714 | — | — | 41,715 |
| Comprehensive income/(loss) | — | — | — | — | — | (17,858) | 190,169 | 172,311 |
| Repurchase and retirement of common stock | (2,351) | (2) | — | — | — | — | (144,491) | (144,493) |
| Balance at December 31, 2022 | 77,762 | $78 | 22,430 | $22 | $630,952 | $(24,630) | $1,239,951 | $1,846,373 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.